

BILL SUMMARY
2nd Session of the 59th Legislature

Bill No.:	SB 1670
Version:	FA1
Request Number:	11041
Author:	Rep. McEntire
Date:	4/25/2024
Impact:	OMES: \$1,500,000

Research Analysis

Pending

Prepared By: House Research Staff

Fiscal Analysis

1670 modifies the requirements of pharmacy benefits managers (PBM) conducting audits on pharmacies under the Pharmacy Audit Integrity Act. The measure creates additional appeals processes for medications in shortage or reimbursed below the pharmacies acquisition cost. When a below-cost reimbursement appeal is denied, PBMs must provide the National Drug Code (NDC) number and the name of the wholesaler(s) where the drug is in stock, within the state, and available for purchase by the dispensing pharmacy at a price below the PBM's reimbursement price. If the NDC number provided is not available below the acquisition cost obtained from the wholesaler whom the dispensing pharmacy purchases majority of the prescription drugs that are dispensed, the PBM must immediately adjust the reimbursement amount and allow the pharmacy to reverse and rebill the claim. If a drug is placed on the FDA Drug Shortages Database, PBMs must reimburse claims to pharmacies at no less than the acquisition cost for the NDC number being dispensed.

Officials from the Employees Group Insurance Division of the Oklahoma Office of Management and Enterprise Services (OMES-EGID) estimate a fiscal impact of One Million Five Hundred Thousand Dollars (\$1,500,000) to the HealthChoice plan annually based on the following claim scenarios, primarily related to the NDC reimbursement portion of the measure.

1. "Pharmacy reimbursement is based off a plan's/PBM's maximum allowable cost (MAC list) for most generics. The cost of individual NDC's MAC reimbursement being below a health plan's reimbursement level – when in aggregate the pharmacy is being reimbursed above cost – could increase due to the appeals process, the FDA's shortage list or other unforeseeable circumstances.
2. The appeal process allows the pharmacy to protest the NDC reimbursement based on the prices from the wholesaler the pharmacy uses, not market averages. Pharmacies could select a higher priced wholesaler and take advantage of this purchasing behavior.
3. The burden of managing such a process could lead to increased reimbursement by a Plan/PBM, broadly raising the reimbursement levels of the MAC lists. This would increase plan and participant costs, in an effort to reduce the risk of fines or penalties.

4. The list of medications on the FDA shortage list could increase this amount to the higher end of the range, assuming significant appeals are submitted.
5. The audit portion of this Bill could have longer-term impacts on the plan as it raises the burden of proof on the auditor. This can lead to more difficulty recouping costs, based on the language requiring 'in writing...suspicion of fraud, willful misrepresentation'.
 - a. While the Bill intends to reduce the burden on ethical pharmacies, unscrupulous pharmacies could take advantage of the added burden on the audit process."

In addition, SB 1670 authorizes the Attorney General (AG) to promulgate rules to implement the provisions of the Pharmacy Audit Integrity Act. Officials from the AG's Office confirmed the requirements of this measure are feasible within current budgetary resources.

Therefore, the fiscal impact on the state budget for FY-25 is \$1,500,000.

The floor substitute is not anticipated to affect the fiscal impact of this measure.

Prepared By: Alexandra Ladner, House Fiscal Staff

Other Considerations

None.